| 吴琳 王丽 魏栋辉 尚铁燕 雷红.紫杉醇联合铂类方案治疗中晚期宫颈癌患者的临床研究[J].,2016,16(5):926-929 |
| 紫杉醇联合铂类方案治疗中晚期宫颈癌患者的临床研究 |
| Clinical Study of Paclitaxel Combined with Platinumin the Treatment ofPatients with Middle-advanced Cervical Cancer |
| |
| DOI： |
| 中文关键词: 宫颈癌 紫杉醇 铂类 |
| 英文关键词: Cervical cancer Paclitaxel Platinum |
| 基金项目: |
|
| 摘要点击次数: 563 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨紫杉醇联合铂类方案对中晚期宫颈癌的临床疗效。方法：98 例中晚期宫颈癌患者平均分为两组，观察组采用紫杉
醇联合铂类方案治疗，对照组采用伊立替康联合铂类方案治疗。分别用电化学发光法、微粒子酶免疫分析法检测血清中人细胞角
蛋白21-1 片段(CYFRA21-1)、人鳞状细胞癌相关抗原(SCC-Ag)含量，对比两种治疗方案的临床疗效、生存质量、副反应。结果：观
察组有效率73.5%显著高于对照组42.9%(P<0.01)。治疗后两组血清CYFRA21-1、SCC-Ag较治疗前均有明显降低(均P<0.05)，且
观察组较对照组降低更明显(P<0.05)。治疗后，两组躯体功能（PF）、情绪功能（EF）、社会功能（SF）、疲乏（FA）、食欲减退（AP）、疼痛
（PA）方面均改善，其中，除EF外，观察组改善均优于对照组(均P<0.05)。观察组副反应总发生率显著低于对照组(P<0.05)。结论：
紫杉醇联合铂类方案对中晚期宫颈癌疗效显著，具有改善患者生存质量、减少副反应、降低血清CYFRA21-1、SCC-Ag 水平的优
点。 |
| 英文摘要: |
| Objective:To explore the clinical efficacy of paclitaxel combined with platinumin the treatment of patients with middleadvanced
cervical cancer.Methods:98 cases of patients with middle-advanced cervical cancer were averagely divided into observation
group and control group, the observation group was treated with paclitaxel combined with platinum, while the control group was treated
with irinotecan combined with platinum. The concentration of serum CYFRA21-1 and SCC-Ag were detected by electrochemiluminescence
immunoassay and microparticle enzyme immunoassay respectively, then compared the clinical efficacy, quality of life, and the side
reactions in two groups.Results:The effective rate in observation group was 73.5%, which was higher than 42.9% in the control group
(P<0.01). The concentration of serumCYFRA21-1, SCC-Ag in two groups after treatment were lower than before treatment(P<0.05), and
the observation group was cut down more significantly than control group (P<0.05). The physical function (PF), emotional function(EF),
social function(SF), fatigue(FA), appetiteloss(AP), pain(PA) in two groups after treatment were improved(P<0.05), among which, except
the EF, the rest in observation group were better than control group (P<0.05). The total incidence of side reactions in the observation
group was significantly lower than control group (P<0.05).Conclusion:Paclitaxel combined with platinum is effective for patients with
middle-advanced cervical cancer, with the advantages of improving the quality of life,reducing side reactions and cutting down the concentration
of serumCYFRA21-1, SCC-Ag. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
